Clinical Nuclear Medicine
https://libcat.nshealth.ca/en/permalink/provcat45206
Hojjat Ahmadzadehfar, Hans-Jürgen Biersack, Leonard M. Freeman, Lionel S. Zuckier, editors.
(Second edition)
--Cham:
Springer
, c2020.
- Available Online
- View e-Book
- Location
- Online
In the new edition of this very successful book, European and North American experts present the state of the art in diagnostic and therapeutic radionuclide procedures. The aim is to examine established and emerging clinical applications in detail, rather than to consider everything included in the comprehensive texts already available within the field. This “practical” approach ensures that the book will be a valuable guide for nuclear medicine physicians, technologists, students, and interest…
- Available Online
- View e-Book
- Responsibility
- Hojjat Ahmadzadehfar, Hans-Jürgen Biersack, Leonard M. Freeman, Lionel S. Zuckier, editors
- Edition
- Second edition
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2020
- Physical Description
- 1 online resource (ix, 1029 p.) : 494 illus., 280 illus. in color
- ISBN
- 9783030394578
- 9783030394554 (Print ed.)
- 9783030394561 (Print ed.)
- Subjects (MeSH)
- Diagnostic Imaging - methods
- Neoplasms - radiotherapy
- Nuclear Medicine
- Specialty
- Diagnostic Imaging
- Medical Oncology
- Radiotherapy
- Abstract
- In the new edition of this very successful book, European and North American experts present the state of the art in diagnostic and therapeutic radionuclide procedures. The aim is to examine established and emerging clinical applications in detail, rather than to consider everything included in the comprehensive texts already available within the field. This “practical” approach ensures that the book will be a valuable guide for nuclear medicine physicians, technologists, students, and interested clinicians alike. This edition of Clinical Nuclear Medicine has been extensively revised to take account of recent developments. The roles of SPECT/CT, PET/CT, and PET/MRI are clearly explained and illustrated, and the coverage extended to encompass, for example, novel PET tracers and therapeutic radionuclides, advanced techniques of brain imaging, and the development of theranostics. Readers will be fully persuaded of the ever-increasing value of nuclear medicine techniques in depicting physiology and function and complementing anatomic modalities such as CT, MRI, and ultrasound.
- Contents
- Part I. Basics -- 1. Physics, instrumentation, and radiation safety and regulations -- 2. Radiopharmaceutical sciences -- 3. Radiomics as applied in precision medicine -- Part II. Diagnostic Nuclear Medicine -- 4. Brain -- 5. Heart -- 6. Lung -- 7. Liver, spleen and biliary tree -- 8. The kidney -- 9. Gastrointestinal system -- 10. Musculoskeletal system -- 11. Application of lymphatic mapping and sentinel node biopsy in surgical oncology -- 12. Lymphoscintigraphy in the management of the lymphatic disorders -- 13. Neuroendocrine system -- 14. Thyroid and parathyroid imaging -- 15. Molecular Imaging of Inflammation and Infection -- 16. Imaging of atherosclerosis with 18F-FDG PET -- 17. PET/CT and PET/MRI Imaging, Normal Variations and Artifacts -- 18. PET in head and neck cancer -- 19. PET in gastrointestinal, pancreatic, and liver cancers -- 20. 18F-FDG-PET/CT in breast and gynecologic cancer -- 21. PET in lung cancer and mediastinal malignancies -- 22. Melanoma -- 23. PET in lymphoma -- 24. PET/CT in renal, bladder and testicular cancer -- 25. PSMA-ligand imaging in the diagnosis of prostate cancer -- 26. Miscellaneous -- 27. Radionuclide imaging of children -- Part III. Nuclear Medicine Therapy -- 28. Radioiodine therapy for benign thyroid disease -- 29. Differentiated thyroid cancer: Radioiodine therapy -- 30. Palliation of metastatic bone pain with radiolabeled phosphonates -- 31. Radionuclide therapy of bone metastases with radium-223 chloride in prostate cancer patients -- 32. Peptide receptor radionuclide therapy -- 33. Treatment of neuroendocrine tumors (neuroblastoma stage III or IV, metastatic pheochromocytoma, etc.) with 131I-mIBG -- 34. Radioimmunotherapy -- 35. Radioactive microspheres -- 36. Radioembolization -- 37. Assessment of tumor response with MRI and CT after radioembolization -- 38. Radioisotope therapy of malignant pleural and peritoneal effusions -- 39. Radiosynoviorthesis (radiation synovectomy) -- 40. Radioligand therapy in prostate cancer using PSMA-ligands.
- Format
- e-Book
- Location
- Online
Management of castration resistant prostate cancer
https://libcat.nshealth.ca/en/permalink/provcat34052
Fred Saad, Mario A. Eisenberger, editors.
--New York:
Humana Press
, c2014.
- Available Online
- View e-Book
- Location
- Online
This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in-depth review of proven therapeutic options, including bone-targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigation are also reviewed. The text provides up-to-date guidelines and algorithms for the management of CRPC bas…
- Available Online
- View e-Book
- Other Authors
- Saad, Fred
- Eisenberger, Mario A.
- Responsibility
- Fred Saad, Mario A. Eisenberger, editors
- Place of Publication
- New York
- Publisher
- Humana Press
- Date of Publication
- c2014
- Physical Description
- 1 online resource (xvi, 337 pages)
- Series Title
- Current clinical urology
- ISBN
- 9781493911769 (electronic bk.)
- 9781493911752
- Subjects (MeSH)
- Drug Therapy, Combination
- Molecular Targeted Therapy
- Prostatic Neoplasms, Castration-Resistant - metabolism
- Prostatic Neoplasms, Castration-Resistant - therapy
- Receptors, Androgen - therapeutic use
- Subjects (LCSH)
- Prostate - Cancer - Treatment
- Oncology
- Interventional radiology
- Abstract
- This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in-depth review of proven therapeutic options, including bone-targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigation are also reviewed. The text provides up-to-date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence-based medicine.
- Contents
- Part I. Castrate-Resistant Prostate Cancer: Clinical and Biological Considerations -- 1. Introduction—Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities -- 2. Evolution of Clinical States and the Castration Resistant Clinical Paradigm -- 3. Molecular Mechanisms of Prostate Cancer Progression After Castration -- 4. New Imaging Modalities -- Part II. Treatment: The Androgen Receptor Signaling Axis Biology and Therapeutic Opportunities, Systemic Chemotherapy, Immunotherapy, Bone Targeted Approaches and Radiopharmaceuticals -- 5. Androgen Receptor Biology in Castration Resistant Prostate Cancer -- 6. The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer -- 7. Approaches Targeting Androgen Synthesis (CYP 17 Inhibitors) -- 8. Cytotoxic Chemotherapy (Taxanes and Taxane Combinations) -- 9. The Emerging Role of Immunotherapy in Castrate- Resistant Prostate Cancer -- 10. Bone-Targeted Therapy: Rationale and Current Status -- 11. Radium-223 and Other Radiopharmaceuticals in Prostate Cancer -- Part III. New Drug Development: Clinical Trials Design in CRPC -- 12. Introduction -- 13. Phase I–II Targeted Treatments -- 14. Defining Clinical Endpoints in Castration-Resistant Prostate Cancer -- Part IV. New Drug Development: Specific Targets -- 15. Angiogenesis Inhibition in Castration-Resistant Prostate Cancer -- 16. Co-targeting Adaptive Survival Pathways -- 17. Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer -- 18. PARP Inhibitors -- 19. Targeting C-Met/VEGF in Castration Resistant Prostate Cancer -- 20. Epigenetics in Castration Resistant Prostate Cancer -- 21. Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype -- Part V. Clinical Management Aspects -- 22. Strategies Addressing Quality of Life: Management of Patient-Reported Outcomes and Symptoms -- 23. Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development.
- Format
- e-Book
- Location
- Online
Management of Prostate Cancer : A Multidisciplinary Approach
https://libcat.nshealth.ca/en/permalink/provcat41438
Michel Bolla, Hendrik van Poppel, editors.
(Second edition)
--Cham:
Springer
, 2017.
- Available Online
- View e-Book
- Location
- Online
This book, now in an extensively revised second edition, provides an exhaustive review of the state of the art in the management of prostate cancer, from screening to treatment, with emphasis on a multidisciplinary approach. The editors are very excited about the outstanding new or updated contributions from the different expert authors. The opening chapters address basic aspects including epidemiology, pathology, biology, genetics, and chemoprevention. The role of individual and mass screening…
- Available Online
- View e-Book
- Other Authors
- Bolla, Michel
- van Poppel, Hendrik
- Responsibility
- Michel Bolla, Hendrik van Poppel, editors
- Edition
- Second edition
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- 2017
- Physical Description
- 1 online resource (viii, 422 pages) : 76 illus., 64 illus. in color
- ISBN
- 9783319427690
- 9783319427683 (print ed.)
- Subjects (MeSH)
- Prostatectomy
- Prostatic Neoplasms - diagnosis
- Prostatic Neoplasms - radiotherapy
- Prostatic Neoplasms - therapy
- Abstract
- This book, now in an extensively revised second edition, provides an exhaustive review of the state of the art in the management of prostate cancer, from screening to treatment, with emphasis on a multidisciplinary approach. The editors are very excited about the outstanding new or updated contributions from the different expert authors. The opening chapters address basic aspects including epidemiology, pathology, biology, genetics, and chemoprevention. The role of individual and mass screening is carefully appraised, and extensive attention is devoted to diagnosis and clinical work-up by means of recently implemented investigations such as multiparametric MRI and choline PET-CT. The use of active surveillance is examined in detail. Subsequent chapters discuss the different therapies that may be employed: open and minimally invasive, including robot-assisted, radical prostatectomy, the various forms of radiation treatment, high-intensity focused ultrasound, cryotherapy, hormonal manipulations, chemotherapy, targeted therapies, and immunotherapy. Up-to-date results from practice-changing phase III randomized clinical trials are included and special insights are provided into the interpretation of results and the patient's perspective.
- Contents
- Epidemiology of prostate cancer in Europe -- Chemoprevention -- Individual and mass screening -- Anatomo-pathology -- Biology -- Genomics -- Radiologic investigations( multiparametric MRI, whole body MRI) -- Nuclear Medecine: follow-up (Choline PET-CT, Radium 223) and treatment of bone metastases -- Diagnosis, clinical work up, TNM classification Markers -- Active surveillance -- Open Radical Prostatectomy -- The robotic laparoscopic radical prostatectomy -- Brachytherapy (Low dose rate) -- Brachytherapy (High dose rate) -- IMRT, hypofractionated irradiation and stereotactic irradiation -- External irradiation + androgen suppression -- Post-operative irradiation: immediate or early delayed?- High Intensity Focused Ultrasound -- Cryotherapy -- Follow-up after radical treatments and relapse -- First line hormonal manipulations -- Upfront chemotherapy at initiation of hormonal treatment for metastatic prostate cancer -- Bone-targeted therapies (Bisphosphonates, denosumab and Radium 223 -- Targeted therapies and vaccination -- How to interprete results -- Prostate EAU guidelines -- Better Patients perspective.
- Format
- e-Book
- Location
- Online
Managing Metastatic Prostate Cancer In Your Urological Oncology Practice
https://libcat.nshealth.ca/en/permalink/provcat40190
K.C Balaji, editor.
--Cham:
Springer
, c2016.
- Available Online
- View e-Book
- Location
- Online
This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practic…
- Available Online
- View e-Book
- Other Authors
- Balaji, K.C
- Responsibility
- K.C Balaji, editor
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2016
- Physical Description
- 1 online resource (xiii, 280 p. : 35 illus., 31 illus. in color)
- ISBN
- 9783319313412
- 9783319313399 (print ed.)
- Abstract
- This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.
- Contents
- Introduction -- Pathophysiology of Castration-Resistant Prostate Cancer -- Androgen Receptor Signaling in Castration Resistant Prostate Cancer -- Non-Androgen Signaling Pathways in Castration-Resistant Prostate Cancer -- Predictive Models in Castration Resistant Prostate Cancer -- Docetaxel in Advanced and Castration Resistant Prostate Cancer -- Combination Treatment Strategies with Docetaxel in Patients with Metastatic Prostate -- Cancer Vaccines in Castration Resistant Prostate Cancer: An evolution in design -- Abiraterone for the treatment of mCRPC -- Enzalutamide in Metastatic Castration Resistant Prostate Cancer -- Radium-223 in Metastatic Castrate Resistant Prostate Cancer -- Cabazitaxel for the Treatment of Prostate Cancer -- Sequencing Therapies in Metastatic Castration Resistant Prostate Cancer -- Bone Preservation Strategies for Men on Androgen Deprivation Therapy -- Novel Therapies in Castration-Resistant Prostate Cancer.
- Format
- e-Book
- Location
- Online
